UK Markets close in 8 hrs 9 mins
  • FTSE 100

    7,104.53
    +72.23 (+1.03%)
     
  • FTSE 250

    23,256.63
    +307.80 (+1.34%)
     
  • AIM

    1,255.03
    +3.92 (+0.31%)
     
  • GBP/EUR

    1.1718
    +0.0008 (+0.07%)
     
  • GBP/USD

    1.3921
    +0.0015 (+0.1072%)
     
  • BTC-GBP

    28,920.95
    -1,108.48 (-3.69%)
     
  • CMC Crypto 200

    979.18
    +29.28 (+3.08%)
     
  • S&P 500

    4,395.26
    -23.89 (-0.54%)
     
  • DOW

    34,935.47
    -149.03 (-0.42%)
     
  • CRUDE OIL

    73.31
    -0.64 (-0.87%)
     
  • GOLD FUTURES

    1,810.60
    -6.60 (-0.36%)
     
  • NIKKEI 225

    27,781.02
    +497.43 (+1.82%)
     
  • HANG SENG

    26,225.32
    +264.29 (+1.02%)
     
  • DAX

    15,659.86
    +115.47 (+0.74%)
     
  • CAC 40

    6,667.84
    +55.08 (+0.83%)
     

Global $10 Billion Bi-Specific MAbS Markets, 2015-2020, 2020-2025F, 2030F

·5-min read

Dublin, June 23, 2021 (GLOBE NEWSWIRE) -- The "Bi-Specific MAbS Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

The global bi-specific MAbS market is expected to grow from $2.93 billion in 2020 to $3.75 billion in 2021 at a compound annual growth rate (CAGR) of 28%.

This report focuses on bi-specific mabs market which is experiencing strong growth. The report gives a guide to the bi-specific mabs market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company, Ltd., Abbott, and AstraZeneca.

The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.

The market is expected to reach $10 billion in 2025 at a CAGR of 28%.

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and finds its applications in the field of drug delivery and cancer immunotherapy.

The bi-specific MAbs market covered in this report is segmented by type into catumaxomab (removab); blinatumomab; duligotumab; SAR 156597. It is also segmented by product type into in vivo; in vitro, by indication into cancer; autoimmune diseases; inflammatory diseases; infectious diseases; microbial diseases; others and by end use into hospitals; research institutes; others.

The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents.

Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. For instance, in June 2020, AbbVie Inc., a US-based biopharmaceutical company entered into a collaboration agreement with Genmab A/S, a Danish biotechnology company, to develop and commercialize antibody therapeutics for cancer treatment.

The companies together will work on three early-stage bispecific antibody candidates of Genmab A/S including DuoHexaBody-CD37, epcoritamab, and DuoBody-CD3x5T4 along with discovering new antibody therapeutics.

Moreover, in July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging bispecific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment.

The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective over monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. According to the World Health Organization, cancer is the second leading cause of death worldwide and is responsible for an estimated 9.8 million deaths in 2018.

Additionally, according to the Centers for Disease Control and Prevention, chronic diseases are among the most prevalent diseases with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases including cancer is anticipated to propel the demand for bi-specific MAbs market to treat these diseases effectively.

Key Topics Covered:

1. Executive Summary

2. Bi-Specific MAbS Market Characteristics

3. Bi-Specific MAbS Market Trends And Strategies

4. Impact Of COVID-19 On Bi-Specific MAbS

5. Bi-Specific MAbS Market Size And Growth
5.1. Global Bi-Specific MAbS Historic Market, 2015-2020, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Bi-Specific MAbS Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. Bi-Specific MAbS Market Segmentation
6.1. Global Bi-Specific MAbS Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Catumaxomab (Removab)

  • Blinatumomab

  • Duligotumab

  • SAR 156597

6.2. Global Bi-Specific MAbS Market, Segmentation By Product Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • In Vivo

  • In Vitro

6.3. Global Bi-Specific MAbS Market, Segmentation By Indication, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Cancer

  • Autoimmune Diseases

  • Inflammatory Diseases

  • Infectious Diseases

  • Microbial Diseases

  • Others

6.4. Global Bi-Specific MAbS Market, Segmentation By End Use, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

  • Hospitals

  • Research Institutes

7. Bi-Specific MAbS Market Regional And Country Analysis
7.1. Global Bi-Specific MAbS Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Bi-Specific MAbS Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Companies Mentioned

  • Johnson & Johnson

  • Novartis AG

  • Hoffmann-La Roche Ltd.

  • Novo Nordisk A/S

  • Bayer AG

  • Thermo Fisher Scientific, Inc.

  • Bistro-Myers Squibb

  • Mylan N.V.

  • Daiichi Sankyo Company, Ltd.

  • Abbott

  • AstraZeneca

  • Eli Lilly

  • Merck & Co. Inc.

  • Amgen Inc.

  • Pfizer Inc.

  • GlaxoSmithKline plc

  • Roche

  • Sanofi

  • Genentech

  • Immunomedics

  • Chugai Pharmaceutical

  • EMD Serono

  • Emergent BioSolutions

  • Jounce Therapeutics

  • MarcoGenics

  • Merus

  • Neovii Biotech

  • NovImmune SA

  • OncoMed Pharmaceuticals

  • Pieris

  • Regeneron Pharmaceuticals

For more information about this report visit https://www.researchandmarkets.com/r/qxx0yn

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting